GILD - Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B | Benzinga
Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share in cash or a total equity value of $4.3 billion.
The addition of CymaBay’s investigational lead product candidate, seladelpar for primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio.
“We are looking forward to advancing seladelpar by leveraging Gilead’s long-standing expertise in treating and curing liver diseases,” said Gilead’s Chairman and CEO, Daniel O’Day.
Related Content: Investors Eye CymaBay’s AFFIRM Study As Regulatory Uncertainties Ease.
PBC is a rare, chronic, cholestatic liver disease mainly affecting women ...